基础医学与临床 ›› 2024, Vol. 44 ›› Issue (10): 1368-1375.doi: 10.16352/j.issn.1001-6325.2024.10.1368

• 研究论文 • 上一篇    下一篇

罗哌卡因减轻LPS诱导的人结肠上皮细胞系NCM-460凋亡

周灵琴1*, 王伟娟1, 任玲玲2, 朱军来1, 陈光兰2   

  1. 丽水市第二人民医院 1.麻醉科; 2.消化科,浙江 丽水 323000
  • 收稿日期:2023-12-28 修回日期:2024-05-15 出版日期:2024-10-05 发布日期:2024-09-27
  • 通讯作者: * zhoulingqin24@126.com
  • 基金资助:
    国家卫生健康委员会“十四五 ”规划全国重点课题(YYWS4176)

Ropivacaine alleviates LPS-induced apoptosis of ulcerative colitis cell line NCM-460

ZHOU Lingqin1*, WANG Weijuan1, REN Lingling2, ZHU Junlai1, CHEN Guanglan2   

  1. 1. Department of Anesthesiology; 2. Department of Gastroenterology, the Second People's Hospital of Lishui, Lishui 323000, China
  • Received:2023-12-28 Revised:2024-05-15 Online:2024-10-05 Published:2024-09-27
  • Contact: * zhoulingqin24@126.com

摘要: 目的 探究罗哌卡因对脂多糖(LPS)诱导的人结肠上皮细胞系NCM-460凋亡和对核苷酸寡聚化结构域(NOD)样受体蛋白3(NLRP3)炎性小体活性的影响。方法 体外培养人结肠上皮细胞系NCM-460,将细胞分组:对照组(control,不干预)、模型组(model,10 μg/mL的LPS处理)、低/中/高浓度组(0.5、1、1.5 mmol/L罗哌卡因干预模型组)。然后将细胞分为对照组、模型组、罗哌卡因组(1.5 mmol/L罗哌卡因干预模型组)、罗哌卡因+抑制剂组(1 μmol/L NF-κB通路抑制剂BAY 11-7082干预罗哌卡因组)、抑制剂组(1 μmol/L NF-κB通路抑制剂BAY 11-7082干预罗哌卡因组)和罗哌卡因+激活剂组(1 μmol/L NF-κB通路激活剂Prostratin干预罗哌卡因组),干预24 h。采用酶联免疫吸附试验(ELISA)检测IL-6、IL-8及肿瘤坏死因子-α(TNF-α)水平;EdU掺入法检测增殖率、Hoechst 33258染色法检测凋亡率;Western blot检测周期蛋白D1(cyclinD1)、半胱氨酸天冬氨酸蛋白酶-3(caspase-3)、NLRP3和NF-κB通路相关蛋白水平。结果 与对照组相比,模型组细胞活力降低,高浓度罗哌卡因组活力升高(P<0.05)。与对照组相比,模型组细胞炎性因子IL-6、IL-8、TNF-α浓度、凋亡率和caspase-3、NLRP3、磷酸化(p)-NF-κB蛋白水平上升(P<0.05),增殖率和cycilnD1蛋白水平下降(P<0.05);与模型组相比,罗哌卡因组和抑制剂组IL-6、IL-8、TNF-α浓度、凋亡率和caspase-3、NLRP3、p-NF-κB蛋白水平下降(P<0.05),增殖能力和cycilnD1蛋白水平上升(P<0.05);与罗哌卡因组相比,罗哌卡因+抑制剂组上述指标趋势变化更加显著(P<0.05),罗哌卡因+激动剂组则显著扭转了这些指标趋势(P<0.05)。结论 罗哌卡因抑制LPS诱导的NCM-460细胞凋亡,促进增殖,NF-κB通路可能参与起作用。

关键词: 人结肠上皮细胞系, 脂多糖, 罗哌卡因, 增殖, 凋亡

Abstract: Objective To investigate the impact of ropivacaine on apoptosis of lippolysaccharide(LPS) -induced ulcerative colitis cell line NCM-460 and on activity of nucleotide oligomerization domain (NOD)-like receptor protein-3 (NLRP3) inflammatome.Methods Human colon epithelial cell line NCM-460 was cultured in vitro and divided into control group (no intervention), model group (10 μg/mL LPS treatment), low/medium/high concentration ropivacaine group (10 μg/mL LPS and 0.5, 1, 1.5 mmol/L ropivacaine co-treatment, respectivoly). Cell viability was determined by cell counting kit 8 (CCK-8) and the appropriate concentration was selected. The cells were then divided into control group, model group, ropivacaine group (10 μg/mL LPS and 1.5 mmol/L ropivacaine treatment) and ropivacaine + inhibitor group (10 μg/mL LPS, 1.5 mmol/L ropivacaine and 1 μmol/L NF-κB pathway inhibitor BAY 11-7082 treatment), inhibitor group (10 μg/mL LPS+1 μmol/L NF-κB pathway inhibitor BAY 11-7082 treatment) and ropivacaine + activator group (10 μg/mL LPS, 1.5 mmol/L ropivacaine and 1 μmol/L NF-κB pathway activator Prostratin), all groups were treated for 24 h. The level of IL-6, IL-8 and TNF-α were detected by enzyme-linked immunosorbent assay (ELISA). The proliferation rate was detected by EdU incorporation. Hoechst 33258 staining microscopy was used to detect the apoptosis rate. Level of cyclinD1, caspase-3, NLRP3 and NF-κB pathway-related proteins were detected by Western blot. Results Compared with the control group, the cell viability of the model group was significantly decreased and the cell viability of high-concentration experimental group was increased after adding ropivacaine (P<0.05). So, 1.5 mmol/L ropivacaine was selected for the follow-up experiment. Compared with the control group, the concentration of inflammatory cytokines IL-6, IL-8, TNF-α, apoptosis rate and the protein expression of caspase-3, NLRP3 and phosphorylated p-NF-κB in model group were all significantly increased (P<0.05), while the proliferation rate and cycilnD1 protein expression were decreased (P<0.05). Compared with model group, the concentrations of IL-6, IL-8, TNF-α, apoptosis rate and the expression of caspase-3, NLRP3 and p-NF-κB protein in ropivacaine group and inhibitor group were significantly decreased (P<0.05), while the proliferation and cycilnD1 protein expression were increased(P<0.05). Compared with ropivacaine group, the trend of the above indexes in ropivacaine + inhibitor group was more significant(P<0.05), and the trend of these indexes in ropivacaine + agonist group was significantly reversed(P<0.05). Conclusions Ropivacaine can inhibit the activation of NLRP3 inflammasome and block the signal transduction of NF-κB pathway, further inhibit LPS-induced apoptosis of NCM-460 cells and promote proliferation.

Key words: human colon epithelial cell line, lipopolysaccharide, ropivacaine, proliferation, apoptosis

中图分类号: